Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Breast Cancer Therapeutics Market

Breast Cancer Therapeutics Market Share

Report ID: GMI466
Published Date: Nov 2023
Report Format: PDF

Download Free Sample

Breast Cancer Therapeutics Market Share

The players operating in this market have established themselves through continuous research & development and ensuring high-quality products. Pfizer, Bristol Myer Squibb, Amgen, F-Hoffmann La Roche, and Merck account for significant market share in the overall breast cancer therapeutics. The leading companies are making substantial investments in product improvements while giving priority to competitive pricing as a strategic approach, anticipating remarkable market expansion.

Market players operating in the breast cancer therapeutics is as mentioned below:

AstraZeneca plc.
Eli Lilly & Co, Inc.
Pfizer, Inc.
Novartis AG
Amgen
F. Hoffmann La Roche AG
Merck & Co, Inc.
Gilead Sciences, Inc.
Eisai Co., Ltd.
Macrogenics, Inc.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global breast cancer therapeutics industry size was around USD 26.7 billion in 2022 and is expected to reach USD 54.7 billion by end of 2032, backed by the growing incidence of breast cancer.

The targeted therapy segment generated revenue of USD 19 billion in 2022 and is anticipating a substantial growth in coming years, attributed to its adaptability for combination with other treatments, the emergence of personalized approaches to enhance clinical outcomes, and continuous advancements.

North America breast cancer therapeutics industry is expected to grow at 6.8% through 2032, owing to the high incidence of breast cancer, steadily rising disease burden, and presence of major players in the region.

AstraZeneca plc, Eli Lilly & Co, Inc., Pfizer, Inc., Novartis AG, Amgen, F. Hoffmann La Roche AG, Merck & Co, Inc., Gilead Sciences, Inc., Eisai Co., Ltd., and Macrogenics, Inc.